IceCure Reports Record 2025 Sales, Advances Regulatory Approvals & Commercial Expansion for ProSense®
Summary
IceCure Medical reported record full-year 2025 sales and highlighted significant operational and regulatory progress for its ProSense® cryoablation system, including new market applications and commercial site expansions.
Key Events
-
Record 2025 Sales Achieved
The company reported record full-year sales of $3.4 million for 2025, driven by growing global adoption of its ProSense® system.
-
Health Canada Application Submitted
IceCure applied to Health Canada to expand regulatory approval for ProSense® to include the treatment of low-risk breast cancer, with a decision expected in the second half of 2026.
-
U.S. Commercial Expansion Plans
The company plans to onboard 30 hybrid commercial-clinical sites across the U.S. for its FDA-approved ChoICE post-marketing study, which will also function as active commercial sites.
-
Expanded Reimbursement Expected
IceCure anticipates expanded reimbursement coverage for low-risk breast cancer procedures following FDA marketing clearance and new medical society guidelines.
Analysis
This 6-K details IceCure Medical's full-year 2025 financial and operational results, emphasizing positive momentum for its ProSense® system. While the company continues to report a net loss, it achieved record sales and outlined several key catalysts for future growth. These include an application to Health Canada for expanded regulatory approval, plans to establish 30 hybrid commercial-clinical sites in the U.S., and anticipated expanded reimbursement coverage. The filing also notes new ProSense® installations at prestigious hospitals and an expected regulatory filing in Japan. These operational advancements provide a positive outlook for product adoption and market penetration, offering a counterpoint to the financial concerns raised in the concurrently filed 20-F.
At the time of this filing, ICCM was trading at $0.71 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $50.1M. The 52-week trading range was $0.54 to $1.53. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.